Before beginning his PhD, Prof. Alkilany launched his career in the FDA-approved pharmaceutical industry, where he gained valuable experience and developed over 20 generic pharmaceutical formulations. Since completing his PhD and transitioning to academia, he has maintained a strong collaboration with the pharmaceutical industry through consulting and joint development projects. One of his key achievements is Q-Silvano hydrogel, the first nanotechnology-based hydrogel registered in Qatar, which resulted from dedicated research in Prof. Alkilany’s lab and a partnership with QLife Pharma in Doha. Below is a brief summary of Prof. Alkilany’s contributions to the pharmaceutical industry.

• Vast experience in the pharmaceutical industry and generic product development, covering pre-formulation, formulation, scale-up, and bio-equivalence trials within an FDA-approved pharmaceutical giant like Hikma Pharmaceuticals (http://www.hikma.com).
• Exceptional theoretical and practical proficiency across various pharmaceutical unit operations, including blending, granulation, drying, milling, compaction, tablet compression/coating, capsule filling, and thorough quality control evaluations.
• Proven track record in seamlessly transferring technology from R&D to production and between production sites, showcasing adeptness at maintaining operational continuity and efficiency.
• Expert command of international regulations such as GMP, GLP, GCP, FDA, EMEA, and ICH guidelines, underscoring a commitment to unparalleled standards of compliance and quality assurance.